Alerus Financial’s Cartesian Therapeutics RNAC Stock Holding History

Alerus Financial’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.4K	Hold	1,000	–	–	﹤0.01%	376
2026 Q1	$6.15K	Hold	1,000	–	–	﹤0.01%	411
2025 Q4	$7.21K	Hold	1,000	–	–	﹤0.01%	378
2025 Q3	$10.2K	Hold	1,000	–	–	﹤0.01%	376
2025 Q2	$10.4K	Buy	+1,000	New	+$10.7K	﹤0.01%	359
2024 Q2	–	Sell	-1,000	Closed	-$19.5K	–	167
2024 Q1	$19.5K	Hold	1,000	–	–	﹤0.01%	161
2023 Q4	$20.7K	Hold	1,000	–	–	﹤0.01%	149
2023 Q3	$31.8K	Hold	1,000	–	–	﹤0.01%	150
2023 Q2	$33.6K	Hold	1,000	–	–	﹤0.01%	155
2023 Q1	$41.7K	Hold	1,000	–	–	﹤0.01%	161
2022 Q4	$33.9K	Hold	1,000	–	–	﹤0.01%	161
2022 Q3	$49K	Hold	1,000	–	–	﹤0.01%	147
2022 Q2	$39K	Buy	1,000 +667	+200%	+$19.8K	﹤0.01%	162
2022 Q1	$12K	Hold	333	–	–	﹤0.01%	178
2021 Q4	$33K	Hold	333	–	–	﹤0.01%	182
2021 Q3	$42K	Hold	333	–	–	﹤0.01%	181
2021 Q2	$42K	Hold	333	–	–	﹤0.01%	190
2021 Q1	$45K	Buy	+333	New	+$41.3K	﹤0.01%	184

Other funds holding RNAC

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Alerus Financial's RNAC Position: Q2 2026 in Review

Alerus Financial held its Cartesian Therapeutics (RNAC) position steady in Q2 2026 at 1,000 shares worth $10.4K. The position accounts for ﹤0.01% of the portfolio, ranked #376.

Alerus Financial first reported a position in RNAC in Q1 2021 and has held it in 18 quarters since. The position peaked at $49K in Q3 2022. 95 funds tracked by Wall St. Rank hold RNAC as of Q2 2026.

Alerus Financial held 1,000 shares of Cartesian Therapeutics worth $10.4K as of Q2 2026.
Alerus Financial left its Cartesian Therapeutics share count unchanged in Q2 2026.
Cartesian Therapeutics made up ﹤0.01% of Alerus Financial's portfolio in Q2 2026, its #376 holding.
Alerus Financial first reported a position in Cartesian Therapeutics in Q1 2021 and has held it in 18 quarters since.
Alerus Financial's Cartesian Therapeutics position peaked at $49K in Q3 2022.
95 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2026.

Based on Alerus Financial's 13F filing for Q2 2026, filed 14 Aug 2026.